| + |
CDKN2A | up-regulates activity 
phosphorylation
|
ATR |
0.402 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-134781 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| 15775976 |
Regulation of NF-kappaB and p53 through activation of ATR and Chk1 by the ARF tumour suppressorInduction of ATR activity in Hs68 E2F1ER cells by endogenous ARF. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| Pathways: | Cell cycle: G1/S phase transition, Cell cycle: G2/M phase transition |
| + |
ZNF304 | down-regulates quantity by repression 
transcriptional regulation
|
CDKN2A |
0.308 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-266098 |
|
|
Homo sapiens |
DLD-1 Cell |
| pmid |
sentence |
| 24623306 |
Finally, we show that ZNF304 also directs transcriptional silencing of INK4-ARF in human embryonic stem cells. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
RUNX1 | up-regulates quantity by expression 
transcriptional regulation
|
CDKN2A |
0.269 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-255713 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| 12091906 |
AML1 binds to a six base pair DNA sequence (TGT/cGGT) that is present in many hematopoietic-specific genes.The p53 promoter does not contain any perfect AML1 DNA-binding sites (TGT/cGGT), but the human p14ARF promoter contains eight such sites (Fig. 1a), as well as multiple sites that match the broader consensus sequence (PyGPy/AGGT) or that have a single change from the consensus site.AML1 regulates the p14ARF promoter through an AML1 consensus DNA-binding site. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| Pathways: | Acute Myeloid Leukemia, Onco-fusion proteins in AML, NPM1_new |
| + |
NPM1 | up-regulates activity
binding
|
CDKN2A |
0.575 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-245073 |
|
|
Mus musculus |
|
| pmid |
sentence |
| 16199867 |
The Arf-NPM interaction seems to be critical in regulating the stability of both proteins. Arf, in fact, induces polyubiquitination and degradation of NPM and inhibits its effects on ribogenesis (18). NPM, instead, protects Arf from degradation and, surprisingly, antagonizes its ability to inhibit cell division |
|
| Publications: |
1 |
Organism: |
Mus Musculus |
| Pathways: | Acute Myeloid Leukemia, DNMT3A in AML, Onco-fusion proteins in AML, NPM1 in AML, AML_TRIPLETS, Triple mutant AML, NPM1_new |
| + |
ZBTB7A | down-regulates quantity by repression 
transcriptional regulation
|
CDKN2A |
0.378 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-225900 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| 15662416 |
Pokemon can specifically repress the transcription of the tumour suppressor gene ARF through direct binding. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
BMI1 | down-regulates quantity by repression
transcriptional regulation
|
CDKN2A |
0.476 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-259359 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| 20551323 |
One important pathway in which bmi-1 acts to promote the overall growth of mice and cellular proliferation includes cdkn2a;bmi-1 represses the expression of cdkn2a, which encodes two cyclin-dependent kinase inhibitors, p16ink4a (p16) and p19arf |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
TBX3 | down-regulates quantity by repression
transcriptional regulation
|
CDKN2A |
0.411 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-249603 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| 25211658 |
TBX2 and TBX3 function as transcriptional repressors and both have been shown to inhibit myogenesis (Carlson et al, 2002; Zhu et al, 2014). Abnormal expression of TBX2 has been reported in several cancers including breast, pancreas, and melanoma, where it has been shown to drive proliferation (reviewed in Abrahams et al (2010)). As has been previously shown in other cell types, TBX2 was found to induce a downregulation of p14/19ARF and function as a direct repressor of p21 in RMS |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
DNA_damage | up-regulates activity
|
CDKN2A |
0.7 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-245493 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| 25101116 |
ARF: a versatile DNA damage response ally at the crossroads of development and tumorigenesis. Alternative reading frame (ARF) is a tumor suppressor protein that senses oncogenic and other stressogenic signals. It can trigger p53-dependent and -independent responses with cell cycle arrest and apoptosis induction being the most prominent ones. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| Pathways: | Cell cycle: G1/S phase transition, Cell cycle: G2/M phase transition |
| + |
Polycomb repressive complex 2 | down-regulates quantity by repression
transcriptional regulation
|
CDKN2A |
0.348 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-259360 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| 22469984 |
The requirement for PRC2 in leukemia is partly because of its role in direct transcriptional repression of genes that limit the self-renewal potential of hematopoietic cells, including Cdkn2a |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
CDKN2A | down-regulates quantity by destabilization
binding
|
NPM1 |
0.575 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-245077 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| 14636574 |
The Arf-NPM interaction seems to be critical in regulating the stability of both proteins. Arf, in fact, induces polyubiquitination and degradation of NPM and inhibits its effects on ribogenesis (18). NPM, instead, protects Arf from degradation and, surprisingly, antagonizes its ability to inhibit cell division |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| Pathways: | Acute Myeloid Leukemia, DNMT3A in AML, Onco-fusion proteins in AML, NPM1 in AML, AML_TRIPLETS, Triple mutant AML, NPM1_new |
| + |
MKRN1 | down-regulates quantity by destabilization
polyubiquitination
|
CDKN2A |
0.379 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-272036 |
|
|
Homo sapiens |
NCI-H1299 Cell |
| pmid |
sentence |
| 23104211 |
Biochemical analyses confirmed that MKRN1 targets p14ARF for ubiquitination and subsequent proteasome-dependent degradation.The Skp1-Cul1-F-box-protein44 (SCF(FBXO44)) complex ubiquitinates full-length BRCA1 in vitro. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
TBX2 | down-regulates quantity by repression
transcriptional regulation
|
CDKN2A |
0.5 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-249594 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| 25211658 |
TBX2 and TBX3 function as transcriptional repressors and both have been shown to inhibit myogenesis (Carlson et al, 2002; Zhu et al, 2014). Abnormal expression of TBX2 has been reported in several cancers including breast, pancreas, and melanoma, where it has been shown to drive proliferation (reviewed in Abrahams et al (2010)). As has been previously shown in other cell types, TBX2 was found to induce a downregulation of p14/19ARF and function as a direct repressor of p21 in RMS |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
TRIP12 | down-regulates quantity by destabilization
ubiquitination
|
CDKN2A |
0.607 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-266781 |
|
|
Homo sapiens |
HEK-293 Cell |
| pmid |
sentence |
| 20208519 |
ULF interacts with ARF both in vitro and in vivo and promotes the lysine-independent ubiquitylation and degradation of ARF. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
CDKN2A | up-regulates quantity by stabilization
|
TP53 |
0.782 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-255694 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| 12091906 |
P14/p19 ARF functions by antagonizing MDM2 and thereby stabilizing p53 (refs. 17,18). Thus, loss of p14/p19ARF impairs p53-mediated growth arrest and/or apoptosis in response to activated oncogenes |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| Pathways: | Acute Myeloid Leukemia, AML1-ETO in AML, DNMT3A in AML, Onco-fusion proteins in AML, NPM1 in AML, AML_TRIPLETS, Cell cycle: G1/S phase transition, Cell cycle: G2/M phase transition, Malignant Melanoma, Triple mutant AML, NPM1_new |
| + |
CDKN2A | down-regulates activity
relocalization
|
MDM2 |
0.757 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-192697 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| 23416275 |
We propose that p14(arf) increases the binding of p53-mdm2 complexes to chromatin, thereby limiting the access of protein deacetylases to p53. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| Pathways: | Acute Myeloid Leukemia, AML1-ETO in AML, DNMT3A in AML, NPM1 in AML, Cell cycle: G1/S phase transition, Cell cycle: G2/M phase transition, Malignant Melanoma, Triple mutant AML, NPM1_new |
| + |
AML1-ETO | down-regulates
transcriptional regulation
|
CDKN2A |
0.2 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-255677 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| 12091906 |
We have identified the p14(ARF) tumor suppressor, a mediator of the p53 oncogene checkpoint, as a direct transcriptional target of AML1 ETO. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| Pathways: | Acute Myeloid Leukemia, AML1-ETO in AML, Onco-fusion proteins in AML |
3.0
CDKN2A
- 
- 